In a promising development, the same scientists who created the BioNTech coronavirus vaccine in coordination with Pfizer have created another vaccine that could “revolutionize” multiple sclerosis treatment by “re-educating” regulatory T-cells to “not only prevent multiple sclerosis, but even reverse some of the effects of the disease,” according to Multiple Sclerosis News Today.
“BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against myelin — delayed the onset and lessened the severity of symptoms in a mouse model of MS, a study reports,” the outlet reports, citing a new study published by the journal Science. “Importantly, treated mice showed no signs of overall immune suppression, suggesting that this type of therapy may overcome the downsides associated with current immunosuppressive therapies for MS.”
As explained by Angus Liu in a report for Fierce Biotech, “Existing treatments work by systemically suppressing the immune system. That can control MS, but it also leaves patients vulnerable to